OB/GYN Clinical Alert – March 1, 2007
March 1, 2007
View Issues
-
New Parents and Mental Disorders
The aim of the present study was to determine the extent to which there is an excess risk of postpartum psychiatric disorders in women vs men. The authors note that postpartum depression afflicts about 10-15% of women and postpartum psychosis about 0.1%. -
Endometrial cancer staging: who should get it?
Case and her co-authors performed a blinded and prospective evaluation of the accuracy of frozen section analysis in a cohort of 60 patients undergoing a surgical staging attempt. Their institutional policy was to formally stage all patients regardless of the uterine tumor characteristics. -
Special Feature: A Limit to Bisphosphonate Treatment
Black and colleagues reported the results of an extension of the alendronate Fracture Intervention Trial (FIT) in which the participants were randomized after 5 years of treatment either to another 5 years of treatment or placebo. -
Psychological Well-being After Hysterectomy
This is a prospective, randomized, multi-centered study from Sweden in which the psychological well-being of 125 women scheduled for hysterectomy was evaluated for up to 6 months post-operative. Of those enrolled, 119 completed the study with 56 undergoing abdominal hysterectomy and 63 having a laparoscopic hysterectomy. -
Osteoporosis and Depression
Silverman and colleagues reported the prevalence of depression in a cross-sectional subset of 3798 women in 6 English-speaking countries, who participated in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. -
New Look on an Old Debate: Neoadjuvant Chemotherapy for Ovarian Cancer
Neoadjuvant Chemotherapy (NACT) for ovarian cancer refers specifically to the administration of cytotoxic therapy ahead of a planned surgical resection usually for primary therapy. -
Pharmacology Watch: Higher HDL Cholesterol in Statin Therapy, Key to Slowing Atherosclerosis?
Citalopram Useful for Depression in CDA Patients; When to Stop Anticoagulation Before Surgery?; Drug Warnings: Ranibizumab and Bevacizumab, Growth Hormone Treatment, More Harm Than Good, FDA Actions -
Clinical Briefs in Primary Care supplement